Weekly Digest - 20-26 May 2023
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - 20-26 May 2023
May 24, 2023: Sitravatinib (IV) / Nivolumab (Opdivo) (IV) / NSCLC / Mirati Therapeutics: Phase 3 SAPPHIRE study did not meet the primary endpoint of overall survival
- The Phase 3 SAPPHIRE study did not meet the primary endpoint of overall survival in the final analysis
- SAPPHIRE is a Phase 3 study evaluating Sitravatinib in combination with Nivolumab vs Docetaxel in patients with 2L/3L NSQ-NSCLC, progressed on prior therapy with chemotherapy and immune checkpoint inhibitor therapy
- The company planned to disclose the study data at a future date
